Cardiolife is pleased to announce it has issued shares to Mayo Foundation for Medical Education and Research.
"We are pleased to welcome the Mayo Foundation for Medical Education and Research as a shareholder. For us, this represents an important milestone in Cardiolife’s journey and our ambition to make advanced cardiovascular diagnostics more accessible and scalable. Our focus remains on developing technology that helps healthcare professionals turn complex cardiac data into clinically meaningful insights," says Kristin Lied, CEO of Cardiolife.
Cardiolife delivers AI-enabled electrocardiogram (ECG) and Holter interpretation that supports scalable, clinically validated cardiovascular diagnostics, integrating seamlessly into existing clinical workflows.
Digital Logic Kardio Software, S.A., operating as Cardiolife, has issued 743 common shares (currently 1% of the company) to Mayo Foundation for Medical Education and Research pursuant to an agreement associated with Cardiolife’s participation in Mayo Clinic Platform_Accelerate.
Under the agreement, Cardiolife retains full ownership of its intellectual property, products, algorithms and commercialization rights.
Cardiolife remains committed to developing clinically relevant, regulatory-compliant AI solutions that integrate into existing healthcare workflows and support better cardiovascular diagnostics worldwide.
***
The share issuance does not constitute an endorsement, certification, validation, or approval of Cardiolife or its products or services by Mayo Foundation for Medical Education and Research or its affiliates.